Breaking News, Trials & Filings

Immune Biosolutions Lead Immunotherapy Neutralizes SARS-CoV-2 Variants

IBIO123 is an inhaled antibody-based immunotherapy in phase 1 and 2 clinical development for the treatment of symptomatic SARS-CoV-2.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Immune Biosolutions’ lead biologic drug candidate demonstrates a potent activity in neutralization assays. Recent results confirmed that IBIO123 is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs), including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy in phase 1 and 2 clinical development for the treatment of symptomatic SARS-CoV-2.   IBIO123 is a cocktail containing 3 recombinant human monoclonal antibodies that sp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters